Business Wire

NY-RISKIFIED

12.3.2024 14:43:30 CET | Business Wire | Press release

Share
Riskified Launches “Auth Rate Enhance” as Part of Chargeback Guarantee to Improve Conversion Rates and Maximize Ecommerce Revenues for Merchants

Riskified (NYSE: RSKD), a leader in ecommerce fraud and risk intelligence, today announced the launch of Auth Rate Enhance, a configuration of Chargeback Guarantee that helps merchants propel ecommerce growth by maximizing authorization rates and approving more online orders without compromising on fraud prevention.

In today’s competitive ecommerce landscape merchants fight to attract and retain customers. But for many shoppers, the journey ends before it truly starts. According to Riskified data, approximately 15% of ecommerce orders fail due to card issuers declining to authorize payment. Meanwhile, Riskified’s data indicates that up to 70% of these declined payments may be from legitimate customers who appear too risky. The impact is massive: false declines were expected to generate a $157B loss (Nuvei) for US merchants alone in 2023. Globally, false declines were set to exceed $443B (Aite-Novarica), far outweighing the projected $48B loss globally from actual ecommerce credit card fraud (Statista).

Overly low authorization rates can choke conversion rates, in turn stunting ecommerce growth. This situation highlights a critical opportunity to optimize the various safeguards within the purchase process to enable merchants to capture more customers and revenue.

Auth Rate Enhance pre-screens orders and enriches the analysis with data points that give issuers such as Capital One the confidence to authorize more digital orders. Furthermore, Riskified’s Chargeback Guarantee offers the flexibility to be configured pre-authorization or a combined approach integrating pre-auth risk assessment with a post-auth feedback loop. This empowers merchants to optimize conversions, reduce insult rate, and offload chargeback risk to Riskified based on the needs of their specific business segments.

"We’re providing an intelligent risk signal to issuers, so they can authorize more ecommerce transactions for our merchants,” said Eido Gal, CEO & Cofounder of Riskified.

"Our integration with Riskified allows us to meaningfully increase our authorization rates by leveraging data from their merchant network, resulting in superior experiences for consumers shopping with Riskified merchants," said Jonathan Borman, Head of Fraud Partnerships, Capital One. The partnership has enabled Capital One to decrease false declines by up to 25% with certain Riskified merchants.

Working with Riskified, athletic apparel retailer Lorna Jane saw an immediate 13% lift in its issuer authorization rate. The retailer also saw a 98% reduction in chargebacks, emphasizing Riskified’s high degree of accuracy in identifying fraud in real-time.

"We were looking for a partner that would not only help us raise our approval and authorization rates, but also minimize fraud to keep us out of the most stringent chargeback programs," said Peter Clarke, Chief Technology Officer at Lorna Jane. "Riskified does exactly that, enabling us to significantly increase our overall authorization rates while also ensuring accurate fraud prevention."

Riskified’s Auth Rate Enhance can help merchants improve their risk profile through accurate fraud prevention, see a significant increase in authorization rates, establish critical trust with card issuers, and take better control of their customer journey.

About Riskified
Riskified (NYSE:RSKD) empowers businesses to unleash ecommerce growth by taking risk off the table. Many of the world’s biggest brands and publicly traded companies selling online rely on Riskified for guaranteed protection against chargebacks, to fight fraud and policy abuse at scale, and to improve customer retention. Developed and managed by the largest team of ecommerce risk analysts, data scientists and researchers, Riskified’s AI-powered fraud and risk intelligence platform analyzes the individual behind each interaction to provide real-time decisions and robust identity-based insights. Learn more at Riskified.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240312888271/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye